β-Adrenoceptors as drug targets in melanoma: novel preclinical evidence for a role of β₃ -adrenoceptors.

ABSTRACT: Stress plays a role in tumourigenesis through catecholamines acting at β-adrenoceptors including β₁ -, β₂ - and β₃ -adrenoceptors, and the use of β-adrenoceptor antagonists seems to counteract tumour growth and progression. Preclinical evidence and meta-analysis data demonstrate that melanoma shows a positive response to β-adrenoceptor blockers and in particular to propranolol acting mainly at β₁ - and β₂ -adrenoceptors. Although evidence suggesting that β₃ -adrenoceptors may play a role as a therapeutic target in infantile haemangiomas has been recently reviewed, a comprehensive analysis of the data available from preclinical studies supporting a possible role of β₃ -adrenoceptors in melanoma was not available. H

SUBMITTER: Dal Monte M 

PROVIDER: S-EPMC6592869 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature